2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Hepatitis B Virus Pre-Core Protein p22 Activates Wnt Signaling

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          An emerging theme for Wnt-addicted cancers is that the pathway is regulated at multiple steps via various mechanisms. Infection with hepatitis B virus (HBV) is a major risk factor for liver cancer, as is deregulated Wnt signaling, however, the interaction between these two causes is poorly understood. To investigate this interaction, we screened the effect of the various HBV proteins for their effect on Wnt/β-catenin signaling and identified the pre-core protein p22 as a novel and potent activator of TCF/β-catenin transcription. The effect of p22 on TCF/β-catenin transcription was dose dependent and inhibited by dominant-negative TCF4. HBV p22 activated synthetic and native Wnt target gene promoter reporters, and TCF/β-catenin target gene expression in vivo. Importantly, HBV p22 activated Wnt signaling on its own and in addition to Wnt or β-catenin induced Wnt signaling. Furthermore, HBV p22 elevated TCF/β-catenin transcription above constitutive activation in colon cancer cells due to mutations in downstream genes of the Wnt pathway, namely APC and CTNNB1. Collectively, our data identifies a previously unappreciated role for the HBV pre-core protein p22 in elevating Wnt signaling. Understanding the molecular mechanisms of p22 activity will provide insight into how Wnt signaling is fine-tuned in cancer.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

          Human hepatitis B virus (HBV) infection and HBV-related diseases remain a major public health problem. Individuals coinfected with its satellite hepatitis D virus (HDV) have more severe disease. Cellular entry of both viruses is mediated by HBV envelope proteins. The pre-S1 domain of the large envelope protein is a key determinant for receptor(s) binding. However, the identity of the receptor(s) is unknown. Here, by using near zero distance photo-cross-linking and tandem affinity purification, we revealed that the receptor-binding region of pre-S1 specifically interacts with sodium taurocholate cotransporting polypeptide (NTCP), a multiple transmembrane transporter predominantly expressed in the liver. Silencing NTCP inhibited HBV and HDV infection, while exogenous NTCP expression rendered nonsusceptible hepatocarcinoma cells susceptible to these viral infections. Moreover, replacing amino acids 157–165 of nonfunctional monkey NTCP with the human counterpart conferred its ability in supporting both viral infections. Our results demonstrate that NTCP is a functional receptor for HBV and HDV. DOI: http://dx.doi.org/10.7554/eLife.00049.001
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene.

            Germ-line mutations of the APC gene are responsible for familial adenomatous polyposis (FAP), an autosomal dominantly inherited disease in humans. Patients with FAP develop multiple benign colorectal tumors. Recently, a mouse lineage that exhibits an autosomal dominantly inherited predisposition to multiple intestinal neoplasia (Min) was described. Linkage analysis showed that the murine homolog of the APC gene (mApc) was tightly linked to the Min locus. Sequence comparison of mApc between normal and Min-affected mice identified a nonsense mutation, which cosegregated with the Min phenotype. This mutation is analogous to those found in FAP kindreds and in sporadic colorectal cancers.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Hepatitis B e antigen and the risk of hepatocellular carcinoma.

              The presence of hepatitis B e antigen (HBeAg) in serum indicates active viral replication in hepatocytes. HBeAg is thus a surrogate marker for the presence of hepatitis B virus DNA. We conducted a prospective study to determine the relation between positivity for hepatitis B surface antigen (HBsAg) and HBeAg and the development of hepatocellular carcinoma. In 1991 and 1992, we enrolled 11,893 men without evidence of hepatocellular carcinoma (age range, 30 to 65 years) from seven townships in Taiwan. Serum samples obtained at the time of enrollment were tested for HBsAg and HBeAg by radioimmunoassay. The diagnosis of hepatocellular carcinoma was ascertained through data linkage with the computerized National Cancer Registry in Taiwan and with death certificates. We performed a multiple regression analysis to determine the relative risk of hepatocellular carcinoma among men who were positive for HBsAg alone or for HBsAg and HBeAg, as compared with those who were negative for both. There were 111 cases of newly diagnosed hepatocellular carcinoma during 92,359 person-years of follow-up. The incidence rate of hepatocellular carcinoma was 1169 cases per 100,000 person-years among men who were positive for both HBsAg and HBeAg, 324 per 100,000 person-years for those who were positive for HBsAg only, and 39 per 100,000 person-years for those who were negative for both. After adjustment for age, sex, the presence or absence of antibodies against hepatitis C virus, cigarette-smoking status, and use or nonuse of alcohol, the relative risk of hepatocellular carcinoma was 9.6 (95 percent confidence interval, 6.0 to 15.2) among men who were positive for HBsAg alone and 60.2 (95 percent confidence interval, 35.5 to 102.1) among those who were positive for both HBsAg and HBeAg, as compared with men who were negative for both. Positivity for HBeAg is associated with an increased risk of hepatocellular carcinoma. Copyright 2002 Massachusetts Medical Society.
                Bookmark

                Author and article information

                Journal
                Cancers (Basel)
                Cancers (Basel)
                cancers
                Cancers
                MDPI
                2072-6694
                31 May 2020
                June 2020
                : 12
                : 6
                : 1435
                Affiliations
                [1 ]The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne 3000, Australia; manht@ 123456unimelb.edu.au (B.M.T.); D.Flanagan@ 123456beatson.gla.ac.uk (D.J.F.)
                [2 ]Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK
                [3 ]The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia; ebert@ 123456wehi.edu.au (G.E.); tran.h@ 123456wehi.edu.au (H.T.); pellegrini@ 123456wehi.edu.au (M.P.)
                [4 ]Department of Medical Biology, The University of Melbourne, Melbourne 3010, Australia
                [5 ]Victorian Infectious Diseases Reference Laboratory, The Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia; Nadia.Warner@ 123456vidrl.org.au
                [6 ]Department of Surgery, Austin Health, The University of Melbourne, Melbourne 3010, Australia; tfifis@ 123456unimelb.edu.au (T.F.); g.kastrappis@ 123456student.unimelb.edu.au (G.K.); c.christophi@ 123456unimelb.edu.au (C.C.)
                [7 ]Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne 3000, Australia; josepht@ 123456unimelb.edu.au
                [8 ]European Cancer Stem Cell Research Institute, Cardiff University, Cardiff CF24 4HQ, UK
                [9 ]School of Pharmacy and Biomedical Sciences, Curtin University, Perth, WA 6102, Australia
                Author notes
                [* ]Correspondence: phesset@ 123456cardiff.ac.uk (T.J.P.); evincan@ 123456unimelb.edu.au (E.V.); Tel.: +44-0-29-2068-849 (T.J.P.); +613 9342 9348 (E.V.)
                Author information
                https://orcid.org/0000-0002-4252-086X
                https://orcid.org/0000-0002-8212-0887
                https://orcid.org/0000-0001-9568-4916
                https://orcid.org/0000-0002-8607-4849
                Article
                cancers-12-01435
                10.3390/cancers12061435
                7352296
                32486480
                7de537c3-6bfc-48c1-9de1-ec859868a697
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 21 April 2020
                : 27 May 2020
                Categories
                Article

                wnt signaling,hepatitis b virus,hbv,cancer,liver cancer,β-catenin,tcf/lef

                Comments

                Comment on this article